This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARRB1 / Beta-arrestin-1 · IHC design guide
Design Immunohistochemistry for ARRB1
This paraffin-section IHC guide describes ARRB1’s cytoplasmic and nuclear staining pattern in most tissues (HPA tissue IHC). Cerebellar Purkinje cells show high staining, while adipocytes are reported as undetected comparators (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARRB1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and nuclear staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Most tissues: cytoplasmic and nuclear; Purkinje cells high (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | GPCR stimulation can redistribute ARRB1 to the membrane (UniProt) | |
| Regulation | No expression regulator annotated (UniProt) | |
| Isoform / epitope | Two isoforms, 1A and 1B; epitope coverage is unspecified (UniProt) |
Section 1
Recommended ARRB1 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with three published ARRB1 protocols for paraffin sections (PMC7974532; PMC7348167; PMC4194125).
| Sample | Paraffin-embedded human kidney tissue; fixative not specified (datasheet M02185) |
| Fixation | Image fixative and duration unreported (datasheet M02185); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit monoclonal (clone CCB-1) anti-ARRB1, 1:50 (datasheet M02185) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARRB1-positive staining in purkinje cells of cerebellum (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and nuclear expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 HIER at 95–98 °C for 20 min (page retrieval specification); a prostate cancer protocol also used pH 9.0 retrieval (PMC4194125: methods).
Section 2
What Is the Expected ARRB1 Staining Pattern?
ARRB1 is expected in the cytoplasm and nuclei of many tissues, with strong IHC staining reported in cerebellar Purkinje cells and nasopharyngeal goblet cells (HPA: Approved; pending external verification; High in both cell types). Cytoplasmic, nuclear, and sometimes membrane-associated signal is biologically plausible because ARRB1 is a non-transmembrane protein that can move between these compartments (UniProt P49407: topology and subcellular location).
| Purkinje cells or nasopharyngeal goblet cells show clear cytoplasmic and/or nuclear staining. | This matches the strongest supplied tissue IHC examples (HPA: High in both cell types; cytoplasmic and nuclear expression in most tissues). Assess the named cell population, rather than treating every cell in the section as equally positive. The HPA tissue profile is Approved but pending external verification (HPA: reliability). |
| Signal is confined to extracellular material, gland lumens, or an apparently sharp cell-surface rim. | An exclusively extracellular or luminal pattern conflicts with ARRB1 lacking a signal peptide and transmembrane segment (UniProt P49407: processing and topology). A membrane rim alone is less decisive: ARRB1 can translocate to the plasma membrane (UniProt P49407: subcellular location). Review morphology and controls before calling a rim specific. |
| Strong staining appears in adipocytes or cardiomyocytes while the intended positive cells remain weak. | Those populations are listed as not detected in the supplied tissue IHC profile (HPA: adipocytes; cardiomyocytes). Their signal warrants investigation for cross-reactivity or endogenous detection activity (general IHC practice). An HPA negative is an observed profile, not proof that every specimen must be negative. |
| Chromogen covers connective tissue, empty spaces, and unrelated cell types with little cell-level contrast. | Broad haze is difficult to reconcile with the reported cellular cytoplasmic and nuclear pattern (HPA: tissue IHC profile). Nonspecific antibody binding, endogenous detection activity, or excessive development can cause such background (general IHC practice). Judge whether recognizable cells retain a distinct compartmental pattern after background is addressed. |
| No signal is visible in an otherwise interpretable Purkinje-cell or nasopharyngeal goblet-cell section. | That conflicts with the supplied High examples (HPA: cerebellum Purkinje cells; nasopharynx goblet cells). Check that the expected cells are present, then examine the antibody, retrieval, detection, and run controls (general IHC practice). HPA's Approved status remains pending external verification (HPA: reliability). |
💡Expected ARRB1 appearanceCall a result consistent when identifiable Purkinje cells or nasopharyngeal goblet cells show strong cellular cytoplasmic and/or nuclear chromogen (HPA: High in both; tissue profile), while dominant extracellular haze or strong staining of HPA not detected adipocytes raises concern for a false positive (HPA: adipocytes; general IHC practice).
| Compartment changes with cell state | ARRB1 is annotated in cytoplasm, nucleus, membrane, coated pits, and vesicles; receptor stimulation can recruit it to the plasma membrane (UniProt P49407: subcellular location). A membrane-adjacent or punctate component can therefore coexist with intracellular staining. This annotation does not predict its intensity in a particular fixed tissue. |
| Topology and processing | ARRB1 has no transmembrane segment or signal peptide and is annotated as a single chain spanning residues 1–418 (UniProt P49407: topology and processing). Interpret dominant extracellular deposits cautiously; these annotations alone cannot identify the source of chromogen or establish an antibody epitope. |
| Antibody and evidence scope | Two listed antibodies have IHC status Approved, whereas the listed antibody with ICC status Supported has no supplied IHC status (HPA: antibody validation). The tissue pattern itself is Approved and pending external verification (HPA: tissue reliability). These labels do not establish that an unlisted catalog antibody reproduces the pattern. |
| Isoforms, modifications, and retrieval | ARRB1 has two annotated isoforms and modified residues, including sites at 47 and 412 (UniProt P49407: isoforms and modified residues). No epitope or target-specific fixation sensitivity is supplied; their effects on staining and retrieval cannot be predicted here. Retrieval optimization is general IHC practice. |
| Situation | Likely cause | Next action |
|---|---|---|
| Known-positive tissue has no chromogen. | The expected cells may be absent from the section, or the IHC detection run may have failed (general IHC practice); HPA reports High Purkinje-cell and goblet-cell staining (HPA: tissue IHC). | Confirm the named cells by morphology and review a working run control, antibody instructions, retrieval conditions, and detection reagents (general IHC practice). Do not infer ARRB1 absence from an uninterpretable run. |
| All tissue compartments show diffuse brown background. | Nonspecific binding, endogenous detection activity, or overdevelopment may obscure the cellular pattern (general IHC practice); HPA describes cytoplasmic and nuclear expression (HPA: tissue profile). | Inspect a no-primary control and the detection controls; adjust blocking, washing, antibody concentration, or development according to the assay controls (general IHC practice). Reassess cell-level localisation after background falls. |
| Adipocytes or cardiomyocytes stain strongly. | These cells are not detected in the supplied HPA examples (HPA: adipose tissue; heart muscle), so cross-reactivity or endogenous detection activity is possible (general IHC practice). | Compare the suspect cells with a known-positive section and a no-primary control (general IHC practice). Report the discrepancy with cell identity and control results; do not treat the HPA profile as an absolute biological exclusion. |
| Only a crisp membrane rim is visible. | Plasma-membrane recruitment is possible (UniProt P49407: subcellular location), but the supplied tissue profile describes cytoplasmic and nuclear expression (HPA: tissue IHC). The rim alone cannot establish specificity. | Check whether positive cells also show credible intracellular staining, compare tissue and assay controls, and describe the observed compartment precisely (general IHC practice). Avoid scoring a membrane-only pattern as the expected tissue pattern without support. |
| Nuclear staining seems unexpected or varies across cells. | Nuclear ARRB1 is plausible: UniProt describes predominantly nuclear monomers, and HPA reports nuclear expression in tissues (UniProt P49407: subcellular location; HPA: tissue profile). Relative nuclear intensity may vary with context, but this section cannot assign a cause. | Verify nuclear boundaries with the counterstain and score nuclear and cytoplasmic signal separately (general IHC practice). Compare the same named cell type across controlled sections before interpreting a change in localisation. |
| Can an IF/ICC image settle an uncertain IHC result? | HPA ICC/IF reports supported nucleoplasmic localisation with additional cytosol, but its listed ICC-supported antibody has no supplied IHC status (HPA: subcellular and antibody records). The modalities have different validation records. | Use the IF/ICC result as compartment context only (HPA: supported nucleoplasm; additional cytosol). Resolve the paraffin-section result with its own IHC controls and an IHC-validated antibody (general IHC practice; HPA: IHC antibody statuses). |
Experiment evidence
IHC & IF images showing ARRB1 staining
M02185 · IHCImmunohistochemical analysis of paraffin-embedded human kidney, using ARRB1 Antibody.
PA2155 · IHCAnti-beta Arrestin 1 antibody, PA2155, IHC(P) IHC(P): Human Mammary Cancer Tissue
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000137486-ARRB1/tissue/cerebral+cortex#imid_20257625
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000137486-ARRB1/tissue/colon#imid_20257535
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000137486-ARRB1/tissue/liver#imid_20257552
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000137486-ARRB1/tissue/kidney#imid_20257553
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA049318; green = ARRB1, blue = nucleus, red = microtubules.
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA049318; green = ARRB1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARRB1 IHC & IF
🧪Run cerebellum first: Purkinje cells should stain (HPA: High in Purkinje cells). Use adipose tissue as the negative tissue (HPA: adipocytes Not detected); on the cerebellar slide, compare Purkinje cells with neighboring cells that show only background staining, without assuming those cells are ARRB1-negative (HPA: only Purkinje cells are specified in the supplied cerebellum row).
Positive control tissue: Cerebellum (Purkinje cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARRB1 in Hep-G2, Rh30, U2OS, NIH 3T3, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include no-primary (secondary-only), a host- and isotype-matched irrelevant antibody for a monoclonal primary or host-matched nonimmune IgG for a polyclonal primary, and an ARRB1 knockout specimen if available (standard IHC control practice). For chromogenic cerebellar IHC, quench endogenous peroxidase and inspect the no-primary slide for residual signal (standard IHC practice).
⚠️Feasibility: A target-specific fixation window and the effect of antigen retrieval are unreported in the supplied evidence; optimize retrieval on the positive control (supplied evidence; standard IHC practice). The selected M02185 caption documents paraffin-embedded kidney IHC but leaves the fixative unreported (M02185 caption). The evidence does not establish that frozen sections or IF are easier; if using cerebellum for IF, assess neuronal autofluorescence with an unstained control (supplied evidence; standard IF practice).
HPA tissue IHC evidence for ARRB1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Purkinje cells | High | Protein (IHC) | HPA → |
| Nasopharynx | Goblet cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Breast | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bronchus | Ciliated cells (cell body) | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Lymph node | Non-germinal center cells | Not detected | Protein (IHC) | HPA → |
| Parathyroid gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ARRB1 IHC Tips
Troubleshoot ARRB1 staining in paraffin section chromogenic IHC by checking retrieval, compartment pattern, controls and scoring (UniProt P49407; HPA tissue IHC).
How should I retrieve ARRB1 in paraffin sections when nuclear staining is weak?
Use Tris-EDTA pH 9.0 heat-induced epitope retrieval at 95–98 °C for 20 minutes (page retrieval rule: nuclear antigen). Let slides cool in the retrieval solution, then compare staining with a section processed through the same run (standard IHC practice). Evaluate nuclear and cytoplasmic signal separately because both patterns are reported in tissues (HPA: cytoplasmic and nuclear expression in most tissues). If staining remains weak, test a shorter or longer heating time on matched sections while keeping buffer and detection conditions fixed (standard IHC practice). Avoid calling a stronger signal specific solely because retrieval increased it; check cellular distribution and controls (standard IHC practice).
Could fixation explain weak or uneven ARRB1 staining in my IHC sections?
The selected M02185 image shows paraffin-embedded human kidney, but its caption does not state a fixative or fixation duration (M02185 tissue-IHC caption). Target-specific sensitivity to fixation is therefore unknown from the supplied evidence (M02185 tissue-IHC caption). Record each specimen’s fixative, time in fixative and processing history, then compare sections with matched retrieval and detection settings (standard IHC practice). Review folds, torn areas and staining gradients before attributing a difference to ARRB1 abundance (standard IHC practice). Keep fixation history distinct from biological interpretation, especially when comparing samples processed in different batches (standard IHC practice).
Should ARRB1 stain nuclei, cytoplasm or membranes in paraffin IHC?
Score nuclear and cytoplasmic staining separately: both occur across many tissues (HPA: tissue IHC profile), and nucleoplasm is the supported principal subcellular location (HPA: subcellular). Membrane, clathrin-coated pit, pseudopodial and vesicular locations are also annotated (UniProt P49407: subcellular location). ARRB1 has no transmembrane segment, so a thin membrane-associated pattern should be assessed against cell morphology rather than treated as an integral membrane outline (UniProt P49407: topology; standard IHC practice). Compare compartments within the same section under identical chromogen development and counterstain conditions (standard IHC practice). Record whether localisation changes with the experimental condition before interpreting a shift in total staining intensity (standard IHC practice).
Can this stain distinguish ARRB1 isoforms or phosphorylation states?
ARRB1 has two annotated isoforms, 1A and 1B, and modified residues include Tyr-47 and Ser-412 (UniProt P49407: isoforms; modified residues). The supplied M02185 caption gives no epitope map or isoform-specific staining claim, so its tissue image cannot establish which isoform or modification generated signal (M02185 tissue-IHC caption). Check an antibody’s documented immunogen or epitope against the sequence feature of interest before making an isoform claim (standard IHC practice). For condition-dependent staining, compare sections using identical retrieval and chromogen development, and confirm modification-specific conclusions with a separately validated reagent (standard IHC practice). Report the result as ARRB1 immunoreactivity when epitope selectivity remains unestablished (standard IHC practice).
How can I check ARRB1 localisation by IF alongside tissue IHC?
Treat IF as a separate assay: the M02185 paraffin-section caption supplies IHC evidence but no IF fixation or permeabilisation conditions (M02185 tissue-IHC caption). Multiplex ARRB1 with a validated marker for the expected cell type, and choose spectrally separated fluorophores after checking tissue autofluorescence with an unstained section (standard IF practice). Because ARRB1 is annotated in the nucleus and cytoplasm and has no transmembrane segment, test permeabilisation suitable for intracellular epitopes against a matched unpermeabilised control (UniProt P49407: subcellular location and topology; standard IF practice). Compare compartment patterns with chromogenic IHC cautiously, since fixation, retrieval and detection differ between assays (standard IHC/IF practice). Acquire control and stained images with the same exposure settings (standard IF practice).
What should I check when ARRB1 chromogenic staining appears diffuse or widespread?
Include a section processed without primary antibody to assess detection-system background, and inspect pigment and tissue edges before scoring (standard IHC practice). Block endogenous peroxidase before peroxidase-based chromogenic detection, and keep DAB development time consistent across comparison sections (standard IHC practice). Diffuse signal alone is inconclusive because cytoplasmic and nuclear expression is reported in most tissues (HPA: tissue IHC profile). Compare cell-level staining with a relevant reference: Purkinje cells show high staining, whereas adipocytes are reported as not detected (HPA: cerebellum; adipose tissue). Adjust antibody concentration or wash conditions only while retaining the same controls and recording each change (standard IHC practice).
How should I quantify ARRB1 when nuclear and cytoplasmic signals differ? ⚠ ANSWER MARKED FOR VERIFICATION
Define nuclear and cytoplasmic regions before scoring because both compartments are reported for ARRB1 (HPA: tissue IHC profile). For each compartment, report the percentage of positive cells and an H-score using intensity categories 0–3; state the threshold and scoring method (standard IHC practice). If counting positive cells per mm², normalise to viable tissue area and report the number of eligible cells or fields (standard IHC practice). Score comparable cell types in matched anatomical regions, since HPA reports different levels among cells and tissues (HPA: tissue IHC profile). Hold retrieval, imaging and chromogen development constant, and exclude folds, edges and necrosis using prespecified rules (standard IHC practice).
How do I distinguish meaningful ARRB1 staining from IHC artefact?
Look for a reproducible cellular pattern that fits cytoplasmic and nuclear ARRB1 staining, while allowing for annotated membrane-associated and vesicular localisation (HPA: tissue IHC profile; UniProt P49407: subcellular location). Check whether signal occurs in the expected cells: Purkinje cells are reported high, while adipocytes are reported not detected (HPA: cerebellum; adipose tissue). Uniform staining at section edges, necrotic areas or folds should trigger an artefact review before biological interpretation (standard IHC practice). Compare no-primary controls to identify endogenous enzyme or detection background, and inspect the counterstain to verify cell boundaries (standard IHC practice). Interpret a changed compartment pattern separately from changed staining intensity (standard IHC practice).
Boster reagents
Best ARRB1 / Beta-arrestin-1 IHC Antibodies
Anti-ARRB1 antibodies have IHC images from paraffin-embedded human kidney and human mammary cancer tissue (catalog IHC captions); both list human, mouse and rat reactivity (catalog reactivity).
Real IHC data
Anti-ARRB1/Beta Arrestin 1 Rabbit Monoclonal Antibody
Cat # M02185
Real IHC data
Anti-beta Arrestin 1/ARRB1 Antibody ®
Cat # PA2155
M02185 lists IHC and ICC/IF and shows IHC on paraffin-embedded human kidney (M02185 applications; M02185 IHC caption). PA2155 lists IHC and shows IHC(P) on human mammary cancer tissue (PA2155 applications; PA2155 IHC caption).
Which to pick: For tissue IHC, choose M02185 when its paraffin-embedded human kidney example fits your sample, or PA2155 for its human mammary cancer tissue IHC(P) example; the captions do not report a fixative (catalog IHC captions). For IF/ICC, choose M02185 because it lists both applications, although no IF image is supplied (M02185 applications; catalog IF image alts). Both list human, mouse and rat reactivity; M02185 is a rabbit monoclonal, while PA2155 lists a rabbit host without a clone designation (catalog reactivity; catalog host and clone fields).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P49407 (ARRB1_HUMAN, Beta-arrestin-1).
- Human Protein Atlas. ARRB1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ARRB1 subcellular location (ICC-IF): Localized to the nucleoplasm..
- Human Protein Atlas. ARRB1 antibody validation summary (3 antibodies).
- ARRB1 Drives Gallbladder Cancer Progression by Facilitating TAK1/MAPK Signaling Activation. Journal of Cancer 2021 — PMC7974532.
- Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis. Frontiers in molecular biosciences 2022 — PMC9538973.
- ARRB1 ameliorates liver ischaemia/reperfusion injury via antagonizing TRAF6-mediated Lysine 6-linked polyubiquitination of ASK1 in hepatocytes. Journal of cellular and molecular medicine 2020 — PMC7348167.
- Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. The EMBO journal 2014 — PMC4194125.
- PubMed PMID:8486659 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:9501202 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARRB1 (Beta-arrestin-1). Expected localisation Cytoplasmic and nuclear staining in most tissues (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: M02185 at 1:50 (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Purkinje cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human kidney tissue; fixative not specified (datasheet M02185); 2. Fixation: Image fixative and duration unreported (datasheet M02185); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit monoclonal (clone CCB-1) anti-ARRB1, 1:50 (datasheet M02185); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: GPCR stimulation can redistribute ARRB1 to the membrane (UniProt); Isoform / epitope: Two isoforms, 1A and 1B; epitope coverage is unspecified (UniProt); Regulation: No expression regulator annotated (UniProt). Evidence: UniProt P49407, HPA tissue IHC · Approved, HPA ICC-IF · nucleoplasm., Datasheet M02185, PMC7974532, PMC7348167. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARRB1/immunohistochemistry-ihc-guide.